Instem (#INS) – adjourned shareholder meeting re. offer to 2nd November, reiterates it recommends the offer

Instem (#INS) – 833p per share recommended offer from ARCHIMED

Instem – trading update, how “delighted” should it be?

Previously writing on company which describes itself as “a leading provider of IT solutions to the global life sciences market” Instem plc (INS), last year with the shares heading below 600p I concluded that more consistent financial delivery is required and I continued to avoid. The shares most recently closed at 620p, though what of them currently heading back towards 600p on a “trading update” announcement?

Instem (#INS) – H1 “broadly in line with management expectations”, notes second half weighting

Instem – interims, emphasises revenue increase and adjusted profit… but what about cash?

Earlier this month I concluded on company which describes itself as “a leading provider of IT solutions to the global life sciences market” Instem plc (INS) that, with the shares up to 660p, greater and more consistent delivery is required – in overall financial terms, not just contract announcements. Now half-year results...and the shares currently down to below 600p.

Instem – “largest ever” contract, but what about the overall financial picture?

Instem plc (INS) has issued a “$12m five-year agreement with Leading CRO”-titled announcement and emphasises it “the largest ever received by Instem”. So what of a current share price response up to 660p?

Instem (#INS) – largest ever contract, agreement to support clinical trial analysis with “a leading global contract research organisation”

Instem – “delighted with the continued successes of our organic and acquisitive growth strategies”. Er!

Describing itself as “a leading provider of IT solutions to the global life sciences market”, Instem (INS) states that it “announces a positive trading update for the six months to 30 June 2022”. How positive?

Instem – argues new project “highlights the strength of our product suite”, what about the recent profit warning?

Life sciences market IT provider Instem (INS) has announced grant funding for involvement in a research project, emphasising it “highlights the strength of our product suite, which supports the continued global demand for reliable alternatives to traditional testing methods - with industry and regulators alike increasingly recognizing the huge benefits of computational toxicology approaches”...

Instem – profit warning, how much recovery ahead?

Life sciences market IT provider Instem (INS) has announced 2021 results emphasising “the combination of increasing demand for regulatory-backed solutions and a growing demand for artificial intelligence and in silico solutions in the drug R&D process underpins our confidence in further leveraging our software and service portfolio”. So what of a current share price response to below 700p, down more than 12%?!

Instem (#INS) – H1 LFL revenue +8%, constant currency +15%

Instem (#INS) – FY20 adj. EPS +6%, confident that well placed

Instem (#INS) – H1 LFL revenue approx. +12%, “a number of potential compelling opportunities for bolt on acquisitions and more substantial targets having been identified”

Instem – “as a result of strong institutional investor demand”, ‘long term shareholders’ including directors sell… at a good price then?

Provider of IT services to the life sciences market, Instem (INS) has announced shareholders including the DG 2008 Discretionary Settlement (of which Chairman David Gare and his wife are trustees) and non-executive director David Sherwin have sold shares… “as a result of strong institutional investor demand following our recent results”. With such demand seemingly unable to be met by the market, a good price in relation to a last close 330p share price then?...

Instem (#INS) – “full year results… now expected to be behind market expectations”

Instem (#INS) £2.5m acquisition of Samarind announced